1. Home
  2. CDLR vs NVAX Comparison

CDLR vs NVAX Comparison

Compare CDLR & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cadeler AS

CDLR

Cadeler AS

HOLD

Current Price

$25.13

Market Cap

1.5B

Sector

N/A

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$9.20

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDLR
NVAX
Founded
2008
1987
Country
Denmark
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
CDLR
NVAX
Price
$25.13
$9.20
Analyst Decision
Hold
Analyst Count
0
9
Target Price
N/A
$10.78
AVG Volume (30 Days)
136.2K
6.1M
Earning Date
11-20-2025
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
2505.89
N/A
EPS
0.90
2.07
Revenue
$632,099,026.00
$1,064,651,000.00
Revenue This Year
$144.16
$58.91
Revenue Next Year
$69.44
N/A
P/E Ratio
$6.69
$4.74
Revenue Growth
198.94
20.27
52 Week Low
$15.37
$5.01
52 Week High
$24.48
$10.65

Technical Indicators

Market Signals
Indicator
CDLR
NVAX
Relative Strength Index (RSI) 82.42 61.16
Support Level $21.51 $9.15
Resistance Level $21.89 $10.20
Average True Range (ATR) 0.51 0.69
MACD 0.35 0.15
Stochastic Oscillator 99.34 68.53

Price Performance

Historical Comparison
CDLR
NVAX

About CDLR Cadeler AS

Cadeler AS is an offshore wind farm vessel contractor. It is engaged in offshore wind farm construction, maintenance, and decommissioning and provides marine and engineering operations to the wind industry, focusing on safety and the environment. The company operates six offshore jack-up wind farm installation vessels. In addition to wind farm installation, these vessels can perform maintenance, construction, decommissioning, and other tasks within the offshore industry.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Share on Social Networks: